Shanghai Yinnuo Pharmaceutical Technology

Peptide therapeutics

Privately held: no public share price · China

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
GLP-1 receptorProtein / enzyme therapeutic
ObesityType 2 Diabetes

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

29 May 2026Topline resultefsubaglutide alfaPhase IIb portion of ENLIGHT (NCT06921486) met its primary endpoint

Financial reports

No financial reports recorded.